newsfilter
← Earnings
Earnings Releases·

Tango Therapeutics — Third Quarter 2026 Earnings Summary

  • Collaboration revenue fell to $0 for the three and nine months ended September 30, 2026, following the August 2025 truncation of the Gilead agreement, which previously generated $53.8 million and $62.4 million respectively in 2025.
  • Net loss widened significantly to $68.4 million ($0.39/share) for the quarter and $169.2 million ($1.08/share) for the nine months, driven by increased R&D and G&A expenses, contrasting with a $15.9 million net income in Q3 2025.
  • The company maintains a strong liquidity position with $977.5 million in cash and marketable securities as of September 30, 2026, sufficient to fund its current operating plan.
  • Strategic focus has shifted to PRMT5-targeted therapies, with a registrational Phase 3 study for vopimetostat plus daraxonrasib in front-line pancreatic cancer expected to initiate in H1 2027 and key data disclosures scheduled for January 2027.
  • Recent ESMO data demonstrated an 82% objective response rate and 88% nine-month progression-free survival for the vopimetostat plus daraxonrasib combination in second- or third-line MTAP-deleted pancreatic cancer, supporting plans to seek accelerated approval in the second-line setting.
Company
TANGO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology